Treating patients with aspirin after completion of standard adjuvant therapy for colorectal cancer failed to significantly ...

Bayer is pressing ... given alongside aspirin plus a P2Y12 inhibitor – at one year. Once again, there was no significant observed increase in bleeding with asundexian at any dose or compared ...

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...

Daily low-dose aspirin reduced the risk for colorectal cancer recurrence by roughly half in patients with mutations in the ...

Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in the PI3K ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says.

For decades, taking a daily low-dose aspirin was a widely accepted practice for preventing heart attacks and strokes. But a ...

People without the risk of heart problems who consumed daily low-dose aspirin, it increased the chance of bleeding in the ...

Description The goal of the trial was to evaluate treatment with famotidine compared with placebo among patients taking low-dose aspirin. Hypothesis Famotidine would be more effective in ...

India's Bayer CropScience Q2 profit falls on pricing pressure November 13, 2024 Europe's main index plunged 2% to a near three-month low on Tuesday ... of the higher dose version of its ...

Bayer shares are trading at a multi-decade low, but shares may still be overvalued. If we add Bayer's net debt of $38.8 billion to Bayer's market cap of $19.7 billion, we can calculate the company ...